Levosimendan Kabi

Levosimendan, the active ingredient in Levosimendan Kabi, is a calcium sensitizer presented as an injectable solution for intravenous use. It is indicated for the management of acute decompensated heart failure and cardiogenic shock in hospitalized patients requiring rapid hemodynamic support.

GNH USA supplies Levosimendan Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with sourcing from EU‑regulated manufacturers. The company ensures quality assurance, cold‑chain logistics where required, and compliance with global regulatory standards.

Levosimendan is used in the cardiovascular therapeutic class to improve cardiac performance in severe heart failure states.

Acute decompensated heart failure: improves cardiac output and reduces pulmonary congestion. Cardiogenic shock: provides inotropic support while reducing afterload. Post‑cardiac surgery low‑output syndrome: helps restore adequate systemic perfusion.

Levosimendan may be associated with several adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Hypotension: transient drop in blood pressure. - Arrhythmias: ventricular or atrial ectopic beats.

Serious or Rare Side Effects: - Severe hypotension: may require vasopressor support. - Ventricular tachycardia: potentially life‑threatening rhythm disturbance. - Allergic reactions: anaphylaxis or severe skin rash.

Levosimendan requires careful clinical monitoring and consideration of patient‑specific factors. - Hemodynamic monitoring: continuous blood pressure and ECG monitoring during infusion. - Renal impairment: adjust infusion rate and monitor renal function. - Hepatic dysfunction: use with caution in patients with liver disease. - Concomitant vasodilators: avoid simultaneous high‑dose nitrates to prevent excessive hypotension. - Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase levosimendan plasma levels. - Concurrent use with other inotropes (e.g., dobutamine): risk of excessive cardiac stimulation. - High‑dose nitrates: can cause profound hypotension.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance hypotensive effect, monitor fluid status. - Beta‑blockers: may blunt desired inotropic response, adjust dosage as needed. - Anticoagulants: monitor for bleeding if hypotension occurs.